Media Center
In the media
AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812
Diari de Sabadell
06/12/2016
Start of a clinical trial with a new drug for lung and endometiral cancer
La Vanguardia online
22/11/2016
European support to the oncology investigation
La Vanguardia
08/04/2015
Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma
Siege to cancer from Bellaterra
L'Econòmic - El Punt Avui
19/02/2013
The biomedical company Ability Pharmaceuticals obtains financing for a pioneering treatment for pancreatic and lung cancer in humans
Financing rounds of Catalan start-ups in 2012
Expansión
04/02/2013
After closing its financing round, Ability Pharmaceuticals – formerly AB-Therapeutics - split from the parent company AB-Biotics and changed its name
AB-Therapeutics raises one million euros and becomes Ability Pharmaceuticals.
Expansión
22/09/2012
LATEST NEWS
19.02.2018
News
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017
News
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017
News
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017
News
Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017
News
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
15.12.2016
News
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016
News
Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016
News
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
